Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example

Item Type:	Article
Title:	Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example
Creators Name:	Fingleton, B. and Lange, K. and Caldwell, B. and Bankaitis, K.V.
Abstract:	This commentary was written as a collaboration between the Board of the Metastasis Research Society and two patients with metastatic breast cancer. It was conceived in response to how preclinical scientific research is sometimes presented to non-scientists in a way that can cause stress and confusion. Translation of preclinical findings to the clinic requires overcoming multiple barriers. This is irrespective of whether the findings relate to exciting responses to new therapies or problematic effects of currently used therapies. It is important that these barriers are understood and acknowledged when research findings are summarized for mainstream reporting. To minimize confusion, patients should continue to rely on their oncology care team to help them interpret whether research findings presented in mainstream media have relevance for their individual care. Researchers, both bench and clinical, should work together where possible to increase options for patients with metastatic disease, which is still in desperate need of effective therapeutic approaches.
Keywords:	Neoadjuvant Chemotherapy, Relapse, Metastatic Progression, Survival
Source:	Clinical and Experimental Metastasis
ISSN:	0262-0898
Publisher:	Springer
Volume:	34
Number:	8
Page Range:	443-447
Date:	December 2017
Additional Information:	Ulrike Stein is a member of the Board of the Metastasis Research Society.
Official Publication:	https://doi.org/10.1007/s10585-017-9872-8
PubMed:	View item in PubMed

Repository Staff Only: item control page